reason report
solid ceo remain bullish conif deal rais estim
bottom line rais estim reiter pt post
 rais convers entir suit
encouragingli ceo ron rittenmey reiter bullish
conif valu creation believ merger spin
entiti current exclus agreement fundament well remain
solid uspi conif gener solid low doubl digit ebitda
growth hospit quarter decent flow weak
driven one timer though guidanc re-affirmed
ebitda goe ebitda estim goe
 pt driven combin ev ebitda multipl
sotp valuat
solid revenu ebitda revenu
ahead street driven strong hospit ss patient
revenu growth despit challeng price flu comp adj
ebitda mm also ahead expect
guidanc re-affirm across board revenu guidanc
 adjust ebitda adjust
dilut ep re-affirmed manag still expect
realiz cost save outlook
incorpor impact potenti conif transact
ceo reiter valu gener opportun conif
encouragingli ceo ron rittenmey reiter bullish
conif valu creation believ merger spin
entiti current exclus agreement
fundament well remain solid uspi segment conif
grow ebitda doubl digit uspi facil system-wid growth
acceler qoq conif post adj ebitda ahead
estim ebitda margin improv robust bp
year ago due on-going cost structur improv
hospit price growth outlook re-affirmed specif
issu cite follow op print acut price bit weaker
expect speak manag view
transient natur larg function high acuiti case mix
year-ago period believ anyth unusu
trend evid op post robust price growth
show macro issu
ev/ebitda analysi sotp
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu figur repres mm bad debt ep present ex one-tim item
pleas refer page import disclosur price chart analyst certif
leverag ratio target around still work
reduc leverag manag remain focus target
flow improv move throughout year
expect manag provid latest thought potenti portfolio
ration call
ebitda goe ebitda estim goe
 pt driven combin ev ebitda
multipl sotp valuat
rais estim reiter pt post rais convers
entir suit encouragingli ceo ron rittenmey reiter bullish
conif valu creation believ merger spin entiti current
exclus agreement fundament well remain solid uspi conif gener
solid low doubl digit ebitda growth hospit quarter decent flow weak
driven one-tim though guidanc re-affirmed ebitda goe
ebitda estim goe pt driven combin ev
ebitda multipl sotp valuat
thc revenu ebitda estim consensu
re-affirmed guidanc outlook repres growth adjust ebitda
mm except per share ise guidanc guidanc svb leerink estimate net earn dilut tenet healthcar corpor
segment guidanceis guidanc guidanc svb leerink estimate hospit othernet oper adj admiss net per adj admiss ebitda segmentnet oper ebitda ebitda less nci net per segmentnet oper net enu adj ebitda tenet healthcar corpor
adjust ebitda outlook unchang
ss adj admiss strong difficult comp flu headwind bp
conif adjust ebitda yoy yoy adjust contract
termin fee
note conif sharehold cathol would spinco sharehold would
own conif
ebitda estim move modestli
newnewnewnewnewnewnewnewnewnewrevenu ni leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkconsensussvb leerinkrevenu expense/net opex/net ni rev/adj admiss inpati admiss equiv admin tenet healthcar corpor
rate outperform price target base combin enterpris
valu ebitda multipl valuat base forward forecast contempl underli
fundament implic sum-of-the-part valuat rang
downsid risk valuat includ
possibl delay medicaid expans current non-expans state
downsid risk leverag
legisl regul cut government commerci payer reimburs
incom statement mm except expensessalari oper total oper ebitda depreci invest ebit net interest pbt incom tax incom yoy incom attribut non-controlling net incom attribut net incom attribut y-o-i chang share million dilut yoy dilut yoy growth expense/net opex/net tenet healar corpor
ana gupt ph certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
rate price target histori tenet healthcar corpor
leerink initi coverag market perform rate septemb
creat bluematrix
rate outperform price target base combin enterpris valu ebitda multipl
valuat base forward forecast contempl underli fundament implic sum-of-
risk valuat
downsid risk valuat includ
possibl delay medicaid expans current non-expans state
downsid risk leverag
legisl regul cut government commerci payer reimburs
rate price target histori inc
lerink place market perform rate januari
creat bluematrix
primari valuat methodolog base rel ev/ebitda rel ev/ebitda track
function compani histori hospit group averag assess potenti ev/ebitda
expans next month base forward forecast contempl underli fundament
implic healthcar reform base rate outperform price target
base ev/ebitda averag ebitda view
risk valuat
downsid risk valuat includ govern reimburs chang part drug inpati outpati
payment updat possibl legisl judici chang coverag expans obamacar across medicaid
expans exchang contract risk privat manag plan consolid acceler shift
rate price target histori inc
leerink initi coverag outperform rate septemb
creat bluematrix
primari valuat methodolog base rel ev/ebitda rel ev/ebitda track
function compani histori hospit group averag assess potenti ev/ebitda
expans next month base forward forecast contempl underli fundament
implic healthcar reform dcf valuat leverag forward forecast wacc termin
growth rate point potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli upsid peer
current trade level base rate outperform price target base
ev/ebitda averag ebitda
risk valuat
downsid risk valuat includ possibl delay medicaid expans current non-expans state
acut care segment highli concentr la vega texa cut govern commerci
payer reimburs declin receiv collect rate pay mix pressur behavior segment
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark issuer
market capit less billion issuer market
capit billion
